Combinostics Oy
About Combinostics Oy
Combinostics Oy is a healthcare AI company that develops and markets advanced, AI-powered software solutions to support clinicians in the early detection, differential diagnosis, and ongoing management of major neurological disorders. Their flagship cNeuro platform integrates quantitative brain imaging biomarkers from MRI, PET, and SPECT scans with other patient data, including demographic information, clinical tests, and neuropsychological assessments. This comprehensive approach provides an intuitive and holistic view of patient data, highlighting important relationships and supporting evidence-based diagnostic and management decisions for physicians.
For radiologists, the cNeuro platform includes applications like cMRI for fully automated brain MRI quantification, cPET for automated amyloid and FDG PET brain quantification, and cDAT for DAT SPECT image quantification. These tools provide objective measurements of brain atrophy, white matter hyperintensities, and tracer uptake, comparing results to normative databases to identify abnormal changes. For neurologists, the cDSI application offers data-driven clinical decision support by combining imaging data with other biomarkers and clinical information, aiding in differential diagnosis, prediction of disease progression, and treatment selection.
Combinostics’ solutions are designed to enhance diagnostic accuracy, improve workflow efficiency, and ultimately contribute to a better quality of life for patients with neurodegenerative diseases. The company’s products are integrated with existing systems like PACS and are utilized by radiology and neurology departments in regions including the EU, US, Japan, and South Korea.
Focus Areas
Business Intelligence
| Key Investors | Industrifonden, NordicNinja VC, BaltCap, Horizon Europe, LEO Innovation Lab, Europa |
| Partnerships | SyntheticMR (acquisition), Arterys, Fountain Health, Siemens Healthineers, TeraRecon |
| Acquisitions | Acquired by SyntheticMR (January 2, 2025) |
| Technology | Cloud-based cNeuro platform, AI-powered solutions, machine learning, integrates imaging and clinical data, disease state fingerprint technology |
| FDA Clearances | 2 cleared products (estimated) |
What Physicians Need to Know
For physicians, Combinostics' solutions offer objective, quantifiable insights that go beyond visual assessment, leading to earlier and more confident diagnoses for neurological disorders. The cDSI application provides a 'second opinion' by comparing patient data to extensive databases of previously diagnosed cases, improving diagnostic consistency and guiding further testing decisions. The integrated, cloud-based cNeuro platform streamlines workflows, enabling comprehensive patient management from early detection and differential diagnosis to longitudinal tracking and treatment planning. This ultimately supports evidence-based decisions and aims to reduce diagnostic delays, allowing for earlier intervention and potentially more effective treatments.
Combinostics' cNeuro platform is cloud-based and designed for comprehensive patient management by connecting its cMRI and cDSI applications with multiple external data sources. They have also partnered with platforms like ConcertAI's TeraRecon Eureka Clinical AI to integrate their cMRI solutions, enhancing seamless workflow integration and providing efficient, quantitative assessment imaging analysis for brain MRI within existing clinical infrastructures.
What the Web Says
Combinostics Oy is a company specializing in AI-powered diagnostic support tools for neurological disorders, particularly dementia and multiple sclerosis. Their cNeuro platform integrates MRI analysis with clinical data to assist radiologists and neurologists in early diagnosis, differential diagnostics, and progression prediction. The company's products are generally well-regarded by healthcare professionals for their utility in providing quantitative information and enhancing communication between disciplines. However, despite innovative products, the company was acquired for a lower valuation than it had raised, suggesting challenges in commercial traction and cash flow.
Overall: MixedStrengths
- cNeuro is a very useful tool for daily dementia and MS investigations.
- Provides quantitative information from scans, aiding in differential diagnosis and assessing cognitive issues.
- Facilitates sharing of imaging information with referring organizations, improving collaboration.
- Automates cross-sectional and longitudinal analysis of atrophy and lesions with PACS integration.
- Backed by over 50 peer-reviewed publications and collaborations with major academic institutions.
- Offers unique biomarkers and reference data for differential reporting of dementia types.
Limitations
- Low adoption rates for their products.
- Acquired for less than the capital raised, indicating potential financial struggles or lack of strong commercial traction.
- Possible cash flow issues without further investor backing.
- Healthtech valuations, especially for AI startups without strong commercial traction, have been under pressure.
Based on reviews from: Combinostics | AI Technology to Support Early Diagnosis, Combinostics - Medical Technology | Issue 36 | February 2021, Free Trial - Combinostics, Combinostics, a 10-year-old radiology and neurology diagnostics AI startup, was acquired by SyntheticMR for less than it raised to date u2026 | by Amine Korchi MD | Medium, Combinostics - Medical Technology | Issue 32 | October 2020
Last updated: 2026-07-17
Videos
News, demos, and interviews about Combinostics Oy.
Videos load interactively. If none appear, search YouTube for Combinostics Oy →
Press & Coverage
Frequently Asked Questions
Related Companies
CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]
Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]
OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]
Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]
MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]
allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]